Última actualización 12 de julio de 2026
Key finding
Mean difference -30.3 mg/dL (−1.7 mmol/L) versus -2.9 mg/dL (−0.2 mmol/L) in control group; p < 0.001.
This study evaluated the effects of adjunctive vildagliptin therapy during Ramadan fasting in adolescents and young adults with type 1 diabetes, finding significant improvements in glucose management.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of adjunctive vildagliptin therapy during Ramadan fasting in adolescents and young adults with type 1 diabetes, finding significant improvements in glucose management.
This research is significant as it provides evidence that vildagliptin can enhance diabetes management during fasting periods, which is crucial for adolescents and young adults who wish to observe Ramadan. Improved glucose control can lead to better health outcomes and reduce the risk of diabetes-related complications.
Limited to a specific population of adolescents and young adults. Results may not be generalizable to older adults or other demographics. Short duration of the study may not capture long-term effects.
Published in
Publication details and source links for this paper.
Nancy SE, Eman ARI. Adjunctive Vildagliptin Therapy During Ramadan Fasting in Adolescents and Young Adults with Type 1 Diabetes: A Randomized Controlled Trial. Diabetology & Metabolic Syndrome. 2023;15:257. doi:10.1186/s13098-023-01232-5
Post-meal glucose surge decreased by 30.3 mg/dL (p < 0.001).
Time in range increased from 77.8% to 84.7% (p = 0.016).
Time above range decreased from 13.6% to 9.7% (p = 0.003).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors and Coefficient of variation, Diabetic ketoacidosis, Mean difference in post-meal glucose surges, and 5 more.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
8
Evidence pairs
187
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Dipeptidyl peptidase-4 inhibitors → Coefficient of variation
Dipeptidyl peptidase-4 inhibitors → Coefficient of variation
Dipeptidyl peptidase-4 inhibitors → Diabetic ketoacidosis
Dipeptidyl peptidase-4 inhibitors → Diabetic ketoacidosis
Dipeptidyl peptidase-4 inhibitors → Mean difference in post-meal glucose surges
Dipeptidyl peptidase-4 inhibitors → Mean difference in post-meal glucose surges
Dipeptidyl peptidase-4 inhibitors → Reduction in Automated Daily Correction Boluses
Dipeptidyl peptidase-4 inhibitors → Reduction in Automated Daily Correction Boluses
Dipeptidyl peptidase-4 inhibitors → Reduction in total bolus dose at the end of Ramadan
Dipeptidyl peptidase-4 inhibitors → Reduction in total bolus dose at the end of Ramadan
Dipeptidyl peptidase-4 inhibitors → Severe hypoglycemia
Dipeptidyl peptidase-4 inhibitors → Severe hypoglycemia
Dipeptidyl peptidase-4 inhibitors → Time above range
Dipeptidyl peptidase-4 inhibitors → Time above range
Dipeptidyl peptidase-4 inhibitors → Time in range
Dipeptidyl peptidase-4 inhibitors → Time in range
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and CGM Time in Range, DPP-4 Inhibitors and Reduction in Automated Daily Correction Boluses.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring CGM Time in Range
Measures CGM Time in Range as a key outcome.
All studies on DPP-4 Inhibitors
Contributes to DPP-4 Inhibitors evidence base.
All studies measuring Reduction in Automated Daily Correction Boluses
Measures Reduction in Automated Daily Correction Boluses as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
DPP-4 Inhibitors may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 1 study
Time above range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
DPP-4 Inhibitors may improve Glucose Variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Coefficient of variation
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
DPP-4 Inhibitors may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
Dipeptidyl peptidase-4 inhibitors appears to improve Mean difference in post-meal glucose surges.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Mean difference in post-meal glucose surges
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
